TheEdgeResearch
Home / Stocks / FMS

Fresenius Medical Care AG & Co. KGaA (FMS)

NYSE Healthcare Medical - Care Facilities
$20.44 ▲ +1.54%
Market Cap
$10.95B
Sector
Healthcare
Industry
Medical - Care Facilities
Beta
0.76
52-Wk Range
20-26.42
CEO
Shervin J. Korangy
Country
DE
Currency
USD

Fresenius Medical Care AG & Co. KGaA operates in the Medical - Care Facilities industry of the Healthcare sector, headquartered in Bad Homburg, HE, DE. The stock last traded at $20.44, up 1.54% on the session, giving a market capitalisation of $10.95B. On trailing twelve-month figures it carries a trailing P/E of 12.58, a net margin of 4.2%. Its beta of 0.76 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
12.58
Price / Sales
0.50
Price / Book
0.77
EV / EBITDA
5.54
Gross margin
26.5%
Operating margin
10.6%
Net margin
4.2%
Return on equity
—
Debt / equity
0.85
Current ratio
0.99
Dividend yield
4.0%
Payout ratio
0.0%
Company profile
Exchange
New York Stock Exchange
Employees
108,165
IPO date
1996-09-17
Headquarters
Bad Homburg, HE, DE
About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.

Comparable companies

Fresenius Medical Care AG & Co. KGaA is most often compared with the following Healthcare names:

AKBADVARMTITVTX
More research on FMS
FMS technical analysis FMS TheEdge Score Compare against peers
Open full interactive analysis & DCF →